What Revolan Treats: Main Uses and Benefits

The primary therapeutic use of Revolan (Piracetam) is applied across domains where additional symptomatic support is needed for certain neurological and cognitive conditions. The medication is commonly used in the symptomatic management of myoclonus of cortical origin, and it plays a role in addressing symptoms like vertigo. The therapeutic role of the medication is aligned with its application in specific clinical presentations.

Revolan is relevant for easing challenging symptoms, including memory loss, lack of concentration, and dizziness, and is also used as an adjuvant therapy for cortical myoclonus. This application supports patients during difficult episodes by easing distress, which generally contributes to easing the overall symptom load. The benefit for older adults and individuals with neurological disorders is that it contributes to support for mental clarity and assists with maintaining functional stability during symptomatic periods. It may also assist with addressing specific challenges like learning difficulties in children with dyslexia.

---

Quick Fact: Support for Key Symptom Domains

• The medication is applied to help manage sudden, involuntary muscle jerks and is relevant for easing challenging cognitive symptoms like lack of concentration, assisting patients with maintaining functional stability during symptomatic periods.

Who Can and Cannot Use Revolan?

The official eligibility for Revolan (Piracetam) is strictly defined by governmental regulatory documentation across several specific population constraints.

Absolute Contraindications prohibit use in patients with the following conditions:

• Cerebral hemorrhage or Huntington's Chorea.
• Severe renal impairment (End-Stage Renal Disease, Creatinine Clearance <20 ml/min).
• Known hypersensitivity to Piracetam or other pyrrolidone derivatives.

Conditional Use and Restrictions

• Renal Function: Patients with mild to moderate renal impairment require conditional use with mandatory dose adjustment based on their creatinine clearance. No adjustment is needed for solely hepatic impairment. Older adults also require regular monitoring of creatinine clearance for dose adaptation during long-term treatment.
• Age: Use is generally not recommended in children under 16 years old for specific regulated indications. Adults are eligible for approved uses, such as the management of cortical myoclonus.
• Pregnancy and Lactation: The medicine should not be used during pregnancy or lactation. Use during pregnancy is restricted to cases of clear necessity where benefits outweigh documented risks.
• Haemostasis: Special caution is required for patients with underlying disorders of haemostasis or risk of bleeding (e.g., major surgery), due to the drug's effect on platelet aggregation.

Revolan Interactions with other medicines and products

This section details the officially documented interaction information for Revolan (Piracetam), based strictly on government regulatory documents.

Official Interaction Classifications

Classification	Documentation Statement
Pharmacokinetic Profile	The potential for pharmacokinetic interaction is low, as Piracetam is minimally metabolized and is primarily eliminated unchanged by the kidneys. Low in vitro inhibition potential on key CYP enzymes, such as CYP3A4/5, is noted but considered clinically insignificant.
Contraindicated Combinations	No specific medicinal product combination is formally classified as a drug-drug interaction contraindication in regulatory labeling.

Documented Interacting Substances

Interactions documented in regulatory summaries are mainly pharmacodynamic, meaning they result in additive or intensified effects.

• Thyroid Hormones ( T3 + T4): Concurrent use with thyroid extract ( T3 + T4) has been reported to lead to symptoms such as confusion, irritability, and sleep disorder, representing an intensified effect.
• Acenocoumarol and Anticoagulants: The co-administration of Piracetam (at high doses) was found to significantly enhance the antiplatelet effects of the anticoagulant Acenocoumarol, resulting in a decrease in parameters related to blood coagulation (e.g., platelet aggregation, fibrinogen levels).

Tested Combinations with No Modification

• Antiepileptic Drugs: Piracetam did not modify the peak or trough serum levels of co-administered antiepileptic medicines, specifically carbamazepine, phenytoin, phenobarbitone, or valproate, indicating a lack of pharmacokinetic interaction with these agents.
• Alcohol: Official documentation states that co-administration of alcohol had no effect on Piracetam serum levels, and Piracetam did not alter alcohol levels. Regulatory summaries do not list mandatory timing separation rules for any co-administered substance.

How Revolan Works: Mechanism of Action

Revolan is a targeted inhibitor that acts by modulating a defined pathway central to cholesterol metabolism. Its mechanism is initiated by binding directly to the circulating protein Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), thereby neutralizing its function.

This binding step prevents PCSK9 from attaching to and facilitating the lysosomal degradation of LDL Receptors (LDLRs) on the surface of liver cells (hepatocytes). The preservation of these functional LDLRs increases their surface density and promotes their continuous recycling back to the cell membrane.

This cellular effect results in an increased capacity of the liver to bind and clear low-density lipoprotein cholesterol (LDL-C) from the plasma. The consequence of this accelerated hepatic uptake and removal of circulating LDL-C is a reduction in systemic lipid levels, which constitutes the core physiological effect produced by Revolan's pharmacodynamic mechanism.

Official Administration Guidelines for Revolan (Eltrombopag)

Revolan is taken once daily as an oral tablet. The exact dosage and duration of treatment are determined by your healthcare provider based on the condition being treated and your weekly platelet count response. Adherence to specific administration rules is critical to ensure proper absorption and effectiveness.

Administration Requirements

Procedure	Guideline
Route & Frequency	Oral tablet, once daily.
Timing Relative to Meals	Must be taken without a meal or with a meal that is low in calcium (e.g., le 50 mg calcium).
Cation Products	Allow at least a 4-hour interval between taking Revolan and any medications or products containing polyvalent cations (e.g., antacids, calcium-rich foods like dairy, mineral supplements containing iron or magnesium).
Dose Titration	The daily dose is adjusted by the physician, typically in mathbf25 mg increments, no more frequently than once every 2 weeks, to achieve and maintain the target platelet count of 50 imes 10^9/L.
Missed Dose	If a dose is missed, do not take the missed dose. Simply take the next scheduled dose on the following day. Do not take two doses to make up for a missed dose.

Age- and Ancestry-Specific Initial Dosing

Initial dosing varies and is dependent on the specific indication, patient age, and genetic background. For adults and children 6 years and older with Immune Thrombocytopenia (ITP), the initial dose is generally mathbf50 mg once daily. However, a reduced starting dose of mathbf25 mg once daily is required for patients of East-/Southeast-Asian ancestry and those with hepatic impairment. Children aged mathbf1 to mathbf5 years with ITP begin at mathbf25 mg once daily.

Research Evidence: Overview of Studies for Revolan (Piracetam)

---

Evidence for the Use in Cortical Myoclonus

Research exploring Revolan for cortical myoclonus—a condition characterized by sudden, involuntary muscle jerks—primarily used Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time. The main study types available were used to examine how the compound was evaluated against a comparison group, with findings in these trials measuring multiple symptom scores. Evidence derived from settings with varying symptom burdens provides context but long-term effects are not fully established.

---

Evidence for Symptomatic Management of Vertigo

The evidence base for vertigo includes Systematic Reviews that analyzed double-blind, placebo-controlled trials. Studies monitored changes in the reported frequency and severity of spinning sensations and associated feelings of imbalance. Research exploring the compound against other comparison groups reported variable findings. Evidence quality varies across studies, as some core research is older and may not align with current methodological standards. The certainty remains low for long-term application.

---

Evidence for General Cognitive Impairment

Research explored the use of Revolan for general cognitive concerns, such as memory loss and lack of concentration, primarily through Meta-analyses of older RCTs. Studies monitored cognitive performance using a variety of psychometric tests. Findings were mixed: studies reported patterns on global clinical impression scales, but research indicates that findings were not consistent when specific, objective cognitive measures were used. Sample sizes were modest, and long-term data are limited.

---

Evidence in Specific Subgroups (Children and Complex Conditions)

Revolan was studied for specific subgroups, including children with learning difficulties, such as dyslexia. This research was often conducted using smaller-scale, double-blind trials. Studies monitored outcomes like reading speed, reading accuracy, and verbal learning tasks. The evidence for this application is limited, and findings were mixed across these trials, with some research describing measured changes for certain subskills while others reported no difference.

---

Long-Term Research and Durability of Study Findings

Studies have explored the long-term use through extended follow-up periods, often in open-label observational settings. These studies monitored symptoms over defined time intervals to gather data on the continued administration of the compound. There is limited information for long-term outcomes from highly controlled, blinded trials, meaning sustained effects over many years are not well characterized.

---

What Remains Uncertain and Research Gaps

The evidence landscape highlights what is known—and what is still uncertain—about Revolan. Evidence quality varies across studies, especially for generalized cognitive conditions. Key limitations include that follow-up durations were often limited across many trials, and specific, objective cognitive measures are not consistently reported in the available research.

Key Studies & References

1. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis (Focus on older people)

Common questions about Revolan (FAQ)

---

Q: What is the main reason doctors prescribe Revolan?

A: According to official product information, Revolan is prescribed to treat low platelet counts (thrombocytopenia) caused by specific health issues. This medicine is used in certain adult and pediatric patients with chronic immune thrombocytopenia (ITP), severe aplastic anemia (SAA), or thrombocytopenia associated with chronic hepatitis C.

Q: Is Revolan a type of antibiotic?

A: No, Revolan is not an antibiotic. Its active ingredient is called eltrombopag, and it is classified as a thrombopoietin receptor agonist. This type of medicine works by helping the body produce more platelets.

Q: How quickly does Revolan start to work?

A: Clinical trial data indicate that after a patient starts taking Revolan, platelet counts may typically begin to increase within a short period. Peak platelet counts are generally observed around 12 to 14 days after starting the medicine.

Q: What is the longest I can expect to take Revolan for?

A: The duration of treatment is highly dependent on the condition being addressed. For some chronic issues, like Immune Thrombocytopenia (ITP), the medicine may be used long-term. For other specific conditions, treatment may be limited to a period of around six months.

Q: Is it true that Revolan is only used for one kind of health issue?

A: No, Revolan is indicated for more than one condition. The official labeling states its use for thrombocytopenia related to chronic Immune Thrombocytopenia (ITP), chronic hepatitis C, and severe aplastic anemia (SAA).

Q: What are the most common side effects people report when taking Revolan?

A: Studies and official information indicate that the most common side effects reported by patients include nausea, fever, cough, and tiredness (fatigue). Other frequently reported reactions are headache and diarrhea.

Q: I've heard Revolan makes you sleepy, is that a common side effect?

A: The official safety information lists tiredness (fatigue) and headache as common reactions. However, specific sleepiness or drowsiness is not listed as a common side effect in regulatory summaries.

Q: Are there any serious side effects of Revolan I should know about?

A: The official labeling includes important safety warnings. These warnings mention the potential for liver damage (hepatotoxicity) and an increased risk of blood clots. The label also notes a warning about potential changes in the bone marrow that necessitate monitoring.

Q: Does taking Revolan affect your ability to drive?

A: Official documents do not include a specific warning against driving while using Revolan. However, reported side effects include dizziness, headache, and extreme tiredness. Patients may wish to monitor how they react to the medicine, as dizziness or tiredness could occur.

Q: Is there a different name for the active ingredient in Revolan?

A: The active ingredient in Revolan is called eltrombopag. When referring to the specific chemical compound in the tablet, it is often called eltrombopag olamine.

Q: Is Revolan safe for older people (seniors)?

A: Official labeling indicates that clinical studies observed no overall differences in safety or effectiveness between older and younger patients who were included in the studies.

Q: What if I have kidney problems, can I still use Revolan?

A: According to regulatory guidelines, a dose adjustment is generally not required for patients who have mild, moderate, or severe kidney impairment.

Q: Is it normal to feel nauseous when starting Revolan?

A: Official safety information lists nausea as a commonly reported side effect in clinical studies of the medicine.

Q: What does the research say about the long-term use of Revolan?

A: The drug's indication for chronic (long-term) conditions such as Immune Thrombocytopenia (ITP) suggests its use is supported for extended periods in those populations.

Q: Are there different strengths of Revolan available?

A: Official product information confirms that Revolan (eltrombopag) is available in multiple tablet strengths. These generally include 12.5 mg, 25 mg, 50 mg, and 75 mg tablets.

Q: How is Revolan eliminated from the body?

A: Official pharmacokinetic information indicates that the medicine is eliminated mainly through the feces. A smaller amount of the medicine is eliminated through the urine.

Q: What is the official classification of Revolan (e.g., controlled substance)?

A: Revolan is officially classified as a thrombopoietin receptor agonist. It is important to note that this medicine is not a controlled substance.

Q: Can I take Revolan if I am breastfeeding?

A: Official guidance describes that a decision should be made regarding either the continuation of the medicine or the continuation of breastfeeding. This decision considers the importance of the medicine for the mother’s health.

Q: Does Revolan need to be refrigerated?

A: Revolan tablets generally do not require refrigeration. Official guidance recommends storing the medicine at room temperature and keeping it protected from moisture.

Q: Is there a generic version of Revolan available?

A: Generic versions of the eltrombopag oral suspension are currently approved and available. However, generic tablets may be subject to various exclusivity rights and may not be available in all regions.

Q: Is Revolan available over-the-counter?

A: Revolan (eltrombopag) is classified as a prescription-only medication. It cannot be obtained without a prescription from a healthcare provider.

Q: What if I take too much Revolan by accident?

A: Official labeling information describes potential symptoms in cases of overdose, which may include a rash, slowed heartbeat, or excessive tiredness. The maximum recommended daily dose is explicitly defined in the regulatory label.

Q: What patient groups were included in the main clinical trials for Revolan?

A: Clinical studies included both adult patients and pediatric patients who were 1 year and older with ITP, as well as patients with chronic Hepatitis C and severe aplastic anemia (SAA).

Q: Are allergic reactions to Revolan common?

A: While the frequency is not detailed, the label describes signs of a serious allergic reaction. These signs include swelling of the face or lips, trouble breathing, and a severe rash. Symptoms such as these are noted as signs that should be promptly reported to a healthcare provider.

Q: Is it necessary to finish the entire course of Revolan, even if I feel better?

A: Studies and official information indicate that Revolan is not a cure for chronic conditions. Official guidance indicates that treatment is typically intended to be continued for the duration prescribed by the physician.

Q: Does Revolan have a black box warning?

A: The medicine carries a Boxed Warning in its official prescribing information. This warning focuses on the risk for hepatic decompensation (worsening liver function) in patients with chronic hepatitis C and the risk of general liver damage (hepatotoxicity).

Q: Can I take Revolan if I am pregnant?

A: Based on animal data, Revolan may cause harm to the fetus. Official product information states that the potential benefit must be weighed against the potential risk to the fetus if the medicine is used during pregnancy.

Q: How long after stopping Revolan do the effects wear off?

A: Official clinical pharmacology information indicates that platelet counts typically begin to decrease after the medicine is stopped. The platelet count may return to the pre-treatment level within approximately four weeks.

Q: Are there any mandatory tests I need before starting Revolan?

A: Official guidelines describe monitoring requirements before and during treatment. Specifically, liver chemistries (blood tests) are required to be measured before starting Revolan and regularly checked throughout the course of treatment.

Q: What is the official regulatory status of Revolan?

A: Revolan (eltrombopag) has received full regulatory approval from agencies like the FDA. It is approved as a Human Prescription Drug under a New Drug Application (NDA) marketing status.

Q: Is Revolan safe to take with common vitamins and supplements?

A: Regulatory guidelines recommend that the medicine not be taken within 4 hours of any product containing polyvalent cations (minerals). This includes many common vitamins and supplements that contain minerals like calcium, iron, magnesium, selenium, or zinc.

Q: Does Revolan interact with grapefruit juice or other foods?

A: Regulatory documents specify that Revolan should be taken either without a meal or with a meal that is low in calcium (no more than 50 mg of calcium). The official information does not contain a specific warning about interaction with grapefruit juice.

Q: Can children take Revolan?

A: Revolan is indicated for use in children. Specifically, it is used for ITP in pediatric patients aged 1 year and older, and for SAA in pediatric patients aged 2 years and older.

Q: What are the main things that make a person ineligible to take Revolan?

A: The official labeling does not list contraindications but provides several Boxed Warnings regarding patient risk. These include warnings for liver damage (hepatotoxicity) and an increased risk of blood clots.

Q: Do I need to eat food when I take Revolan?

A: The medicine is not required to be taken with food. Regulatory documents state that it should be taken either without a meal or with a meal that is very low in calcium (leq 50 mg).

Q: Can Revolan cause liver problems?

A: The official labeling includes a Boxed Warning that the medicine may cause liver toxicity (hepatotoxicity). This risk requires mandatory and regular monitoring of liver chemistries (blood tests).

Q: Why do different doctors prescribe different doses of Revolan?

A: Dosing is highly individualized and is determined by several factors outlined in the regulatory documents. These factors include the specific condition being treated, the patient's age, and specific patient characteristics like ancestry or the presence of hepatic impairment.

Q: Does Revolan have any known interactions with herbal supplements?

A: While specific herbal supplements are not listed, the medicine should not be taken within 4 hours of any product containing polyvalent cations. This precaution applies to any herbal supplements that may contain minerals such as iron or calcium.

Official Storage and Disposal Requirements

Revolan (Piracetam) must be stored according to specific regulatory conditions to maintain its quality and potency. The product is required to be kept at a controlled room temperature, typically maintained below 25 C or 30 C depending on the label.

Storage Constraint	Requirement
Temperature	Store below 25 C or 30 C; Do not freeze
Environmental	Protect from light and moisture; Keep container tightly closed
Child Safety	Store out of the sight and reach of children

Maintaining these conditions is essential for the product’s labeled stability and shelf-life. Expired or unused Revolan must be handled responsibly: follow official drug take-back programs or sanctioned household disposal procedures, and ensure the medicine is not discarded into wastewater or the general household trash.